glp-1 vs sglt2 weight loss Combining inhibitor and agonist: exaggerated in a morbidly obese patient with type 2 diabetes Lilly orforglipron oral GLP-1 phase

24K Chicken Bone Broth

(NYSE: PFE) announced positive topline results from the phase 2b VESPER-3 study investigating monthly maintenance dosing of its fully-biased, ultra-long-acting, injectable GLP-1 receptor agonist (RA) PF3944 (MET-097i) in adults with obesity or overweight without type 2 diabetes

Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, et al

, Sabatier, E

This can lead to more regular menstrual cycles and better management of other PCOS symptoms

There are also less common but important risks including gallbladder disease, pancreatitis, dehydration from vomiting or diarrhea, worsening reflux or gastroparesis symptoms